Eupraxia Pharmaceuticals Inc. (EPRX.TO)
CAD 4.59
(-2.34%)
CAD 4.59
(-2.34%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.58 CAD | -28.1% |
| 2022 | -1.21 CAD | 24.84% |
| 2021 | -1.61 CAD | -419.35% |
| 2020 | -0.31 CAD | 44.64% |
| 2019 | -0.56 CAD | 45.63% |
| 2018 | -1.03 CAD | -202.94% |
| 2017 | -0.34 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.23 CAD | 39.29% |
| 2024 Q1 | -0.28 CAD | -86.67% |
| 2023 Q3 | -0.25 CAD | 30.56% |
| 2023 FY | - CAD | -30.58% |
| 2023 Q4 | -0.15 CAD | 40.0% |
| 2023 Q2 | -0.36 CAD | -56.52% |
| 2023 Q1 | -0.23 CAD | 43.9% |
| 2022 Q2 | -0.31 CAD | -19.23% |
| 2022 Q4 | -0.41 CAD | -86.36% |
| 2022 FY | - CAD | 24.84% |
| 2022 Q1 | -0.26 CAD | 13.33% |
| 2022 Q3 | -0.22 CAD | 29.03% |
| 2021 Q2 | -0.41 CAD | 63.72% |
| 2021 Q4 | -0.30 CAD | 14.29% |
| 2021 Q1 | -1.13 CAD | -10460.75% |
| 2021 FY | - CAD | -419.35% |
| 2021 Q3 | -0.35 CAD | 14.63% |
| 2020 Q2 | -0.08 CAD | 55.06% |
| 2020 FY | - CAD | 44.64% |
| 2020 Q4 | -0.01 CAD | 87.01% |
| 2020 Q3 | -0.08 CAD | -7.85% |
| 2020 Q1 | -0.17 CAD | 0.0% |
| 2019 Q3 | -0.14 CAD | 0.0% |
| 2019 FY | - CAD | 45.63% |
| 2019 Q4 | - CAD | 100.0% |
| 2018 FY | - CAD | -202.94% |
| 2017 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Appili Therapeutics Inc. | -0.03 CAD | -4964.103% |
| Helix BioPharma Corp. | -0.21 CAD | -652.381% |
| Microbix Biosystems Inc. | -0.00 CAD | -526566.667% |
| Medicenna Therapeutics Corp. | -0.37 CAD | -327.027% |
| Satellos Bioscience Inc. | -0.18 CAD | -777.778% |
| Oncolytics Biotech Inc. | -0.41 CAD | -285.366% |
| Sernova Corp. | -0.13 CAD | -1115.385% |